Bao et al. [21] |
124 |
RCT, open label |
Immediate intervention |
Xiaozheng Zhitong Paste |
Ointment |
Multiple cancers with metastases |
China |
Control is not a placebo |
|
Belcaro et al. [22] |
80 |
RCT, open label |
60 days |
Meriva (lecithin delivery system of curcumin) |
Oral |
Chemo/radiotherapy postsurgical and multiple cancers |
Italy |
Heterogeneous cancer study population |
|
Brooker et al. [23] |
66 |
RCT, blinded |
12 months |
IH636 grape seed proanthocyanidin extract |
Oral |
Pain after high-dose radiotherapy for early breast cancer |
UK |
None |
|
Costa Fortes et al. [24] |
56 |
RCT, blinded |
6 months |
Agaricus silvaticus fungus extract |
Oral |
Postsurgical patients with colorectal cancer and pain |
Brazil |
Integrity of double-blinding unclear |
|
Pawar et al. [27] |
27 |
RCT, blinded |
50 days |
SAMITAL (three botanical extracts) |
Oral solution |
Pain from oral mucositis in patients treated for neck/head cancer |
India |
Control versus exposure group inequity |
|
Pommier et al. [25] |
254 |
RCT, open label |
6 weeks |
Calendula (plant) |
Ointment |
Pain after radiotherapy for breast carcinoma |
France |
Integrity of blinding questionable |
|
Tröger et al. [26] |
220 |
RCT, open label |
12 months |
Mistletoe |
S/C injections |
Pancreatic cancer |
Serbia |
Not blinded |
|
Total |
827
|
|
|
|
|
|
|
|